June 23, 2025 06:30 AM EDTUpdated 12:40 PM
R&D

Up­dat­ed: Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, yet stock plum­mets

Ayisha Sharma

News Reporter

Com­pass Path­ways said Mon­day its psilo­cy­bin drug has cleared the first of two late-stage tests in a chal­leng­ing form of de­pres­sion as it ad­vances to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

No­vo ends short-lived part­ner­ship with Hims over com­pound­ed obe­si­ty drugs

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

Lil­ly’s bima­grum­ab boosts weight and fat loss when added to Novo's We­govy

Ex­elix­is' pos­i­tive Phase 3 col­orec­tal can­cer da­ta boost stock

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times